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COMMENTARY
Metastatic breast cancer (MBC) is a heterogeneous disease that has 
a variety of different clinical scenarios, ranging from solitary met-
astatic lesions to diffuse and multiple organ involvement. Overall, 
survival of patients with MBC is slowly but steadily improving 
(1)—the risk of death is decreasing by 1%–2% each year (2). The 
greatest improvement is most probably related to the development 
and widespread availability of modern systemic therapies (3). In 
addition, modern diagnostic tools allow the detection of early met-
astatic disease, which may be more responsive to treatment than 
late metastatic disease (4,5). However, earlier diagnosis of meta-
static disease may also result in a lead time bias, falsely increasing 
the survival times of these patients (2).
A distinctive subset of MBC patients who are most likely to 
gain substantial benefit from an intensified multidisciplinary ther-
apeutic  approach  is  represented  by  “oligometastatic”  disease, 
which is characterized by solitary or few detectable metastatic le-
sions that are usually limited to a single organ. This population of 
“potentially curable” stage IV disease is estimated to be 1%–10% 
of  newly  diagnosed  MBC  patients  (6).  The  existing  guidelines 
(National  Comprehensive  Cancer  Network  [NCCN]  Clinical 
Practice Guidelines in Oncology, European Society for Medical 
Oncology [ESMO] Clinical Recommendations) list surgery, radi-
ation, and regional chemotherapy as possible therapeutic options 
in patients with localized metastatic disease (7,8).
The European School of Oncology–Metastatic Breast Cancer 
(ESO–MBC)  Task  Force  addressed  the  management  of  these 
patients in its first consensus recommendations, stating: “A small 
but very important subset of MBC patients, for example those with 
a solitary metastatic lesion, can achieve complete remission and a 
long survival. A more aggressive and multidisciplinary approach 
should be considered for these selected patients. A clinical trial 
addressing this specific situation is needed” (9).
At the European Breast Cancer Conference (EBCC)-6, held in 
Berlin in March of 2008, the second public session on MBC guide-
lines  addressed  the  controversial  issue:  “Can  metastatic  breast 
cancer be cured?” Historically, such an approach was not consid-
ered  worthwhile  because  most  patients’  disease  subsequently 
recurred because of undetected additional microscopic metastatic 
foci. The promising results of recent series of MBC patients un-
dergoing  “curative”  surgery  or  radiotherapy  both  for  primary 
tumor and distant metastases and the long-term survival achieved 
with  modern  systemic  therapies  raised  justified  interest  and 
renewed the discussion on this complex topic. However, the value 
of such strategies has not been tested in prospective randomized 
trials and is not well recognized. In this commentary, the avail-
able data supporting the local (surgery and radiotherapy) and 
chemotherapy options, possibly associated with cure in MBC, 
are presented and discussed in detail.
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A distinctive subset of metastatic breast cancer (MBC) is oligometastatic disease, which is characterized by single or few detect-
able metastatic lesions. The existing treatment guidelines for patients with localized MBC include surgery, radiotherapy, and 
regional chemotherapy. The European School of Oncology–Metastatic Breast Cancer Task Force addressed the management of 
these patients in its first consensus recommendations published in 2007. The Task Force endorsed the possibility of a more 
aggressive and multidisciplinary approach for patients with oligometastatic disease, stressing also the need for clinical trials in 
this patient population. At the sixth European Breast Cancer Conference, held in Berlin in March 2008, the second public session 
on MBC guidelines addressed the controversial issue of whether MBC can be cured. In this commentary, we summarize the 
discussion and related recommendations regarding the available therapeutic options that are possibly associated with cure in 
these patients. In particular, data on local (surgery and radiotherapy) and chemotherapy options are discussed. Large retrospec-
tive series show an association between surgical removal of the primary tumor or of lung metastases and improved long-term 
outcome in patients with oligometastatic disease. In the absence of data from prospective randomized studies, removal of the 
primary tumor or isolated metastatic lesions may be an attractive therapeutic strategy in this subset of patients, offering rapid 
disease control and potential for survival benefit. Some improvement in outcome may also be achieved with optimization of 
systemic therapies, possibly in combination with optimal local treatment.
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Identification of MBC Patients Suitable for 
Curative Treatment
The unpredictable clinical behavior of MBC reflects the biological 
heterogeneity of the disease. The major task is therefore to identify 
predictive  and  prognostic  models  facilitating  the  selection  of 
patients likely to benefit from curative options.
The development of modern technologies has enabled scientists 
to  further  classify  breast  tumors  by  measuring  differences  in 
thousands of biological pathways simultaneously. Gene expression 
profiling may identify tumors that are likely to metastasize, perhaps 
even the location of the metastases (10), and may identify predictive 
markers of sensitivity to different therapies. As a result, each patient 
would be offered an individualized treatment associated with the 
highest  probability  of  therapeutic  benefit  (potentially  leading  to 
cure) and the smallest risk of resistance (11). Recent advances in 
pharmacogenetics may also allow the selection of the therapeutic 
options associated with the lower toxicity and higher therapeutic 
efficacy for the individual patient. In addition, improved diagnostic 
tools (such as positron emission tomography and detection of circu-
lating tumor cells) (4,12) will possibly improve the identification of 
truly solitary metastatic lesions and/or minimal drug-resistant re-
sidual disease that is susceptible to effective local treatments (10).
Definition of Cure and Appropriate Endpoints
Most trials in MBC have relatively short follow-up. Long-term 
surveillance (>3–5 years) is exceptional, so little is known about 
the definitive outcome and the exact proportion of long-term 
survivors.
Complete response (CR), as assessed by conventional or mod-
ern imaging, and long-term progression-free survival have usually 
been  used  as  surrogates  for  cure  in  MBC.  However,  with  the 
advent of new technologies, we are now able to detect minimal 
residual disease, which may influence the definition of cure.
Long-term survival may simply reflect the indolent nature of 
the disease, rather than the impact of therapy. However, “cure” 
does not necessarily mean destroying every cancer cell, but rather 
rendering  the  disease  harmless  (without  clinically  significant 
adverse effects) for prolonged periods (13), which often can be 
achieved with less toxic therapies such as hormonal or targeted 
agents. Other clinical endpoints, such as tumor response, disease 
control, or time to progression are often used to replace overall 
survival (OS) in the ability to assess the long-term benefit of 
selected  treatment  strategies  (14,15).  Importantly,  the  ultimate 
goal in MBC management is to prolong the duration of life while 
maintaining a good quality of life. New endpoints must therefore 
be defined to assess this global definition of cure.
The Role of Systemic Treatment
Many reports from prospective clinical trials examine the effects 
of endocrine, cytotoxic, targeted, or combination treatments in 
MBC. Despite initial response, most patients develop progressive 
disease within 12–24 months, the median survival of endocrine 
nonresponsive or resistant MBC is 18–24 months, and less than 
5% of patients live 5 years.
However, some patients who achieve a CR remain free of overt 
disease for prolonged periods, sometimes even beyond 20 years 
(16,17).  These  long-term  survivors  are  usually  young  and  have 
good performance status and limited metastatic disease. Although 
this fraction represents a minority of patients (between 1% and 
3%), this finding challenges the common belief that MBC is uni-
versally fatal and raises the question of curability of this disease. In 
this regard, the oncology community is often divided in apparently 
opposite attitudes. On one side, there are those who believe that all 
patients  deserve  the  most  intensive  treatment  available,  even  if 
asymptomatic and at any cost of side effects, to offer them the 
small chance of achieving a durable CR. On the other side, there 
are those who believe that only palliation can be offered to these 
patients because MBC is virtually incurable. A more balanced 
view is a quality of life–oriented approach, choosing personalized 
treatments with a reasonable risk to benefit ratio and taking into 
account the patient’s own attitude in guiding them toward more or 
less intensive therapy.
Recent therapeutic developments, such as the introduction of 
new cytotoxic agents (taxanes, vinorelbine, capecitabine, gemcit-
abine,  liposomal  anthracyclines,  etc),  newer  hormonal  agents, 
(third-generation aromatase inhibitors and fulvestrant), and bio-
logical therapies (trastuzumab, lapatinib, and bevacizumab), have 
resulted in constant improvements in treatment efficacy and con-
sequently in MBC outcome (16).
An  OS  improvement  was  shown  in  two  recent  cohorts  of 
patients with MBC as compared with the previous 20 years (2,3). 
In a population-based study of 2150 patients from British Columbia 
(3), women treated in 1999–2001 had a statistically significantly 
better survival than those treated in 1997–1998 (median of 667 
days and 564 days, respectively), and both cohorts had statistically 
significantly better survival than those treated in 1991–1992 and 
1994–1995 (median of 438 days and 450 days, respectively). The 
greatest differences in survival in the latter two cohorts were 
attributed to the introduction of aromatase inhibitors, taxanes, 
and trastuzumab. The question remains in how many patients, 
these improvements would actually translate into cure.
Most data on long-term survival in MBC come from consecutive 
studies conducted at the University of Texas MD Anderson Cancer 
Center. In a series of 1581 patients treated with consecutive first-
line standard-dose doxorubicin and alkylating agent combinations 
between 1973 and 1982, 263 (16.6%) patients achieved a CR and 49 
(3.1%) remained free of disease for more than 5 years (18). After a 
median follow-up of 191 months, 26 patients (1.5%) remained in 
first CR and four patients died in CR after 118–234 months. A 
substantial decrease in the risk of progression was observed after 
approximately  3  years  from  initiation  of  therapy,  dropping  to  a 
sustained 2% after 4 years, thus, stressing the need of long-term 
follow-up in MBC. The number of metastatic sites was lower in 
patients with long-term CRs than in the total patient population or 
in the total CR group. The CR rate was similar in patients with 
estrogen receptor (ER)-positive (14%) and ER-negative tumors 
(11%), but patients with ER-positive disease had, overall, statistically   
significantly better progression-free survival and OS (19). Another 
series of 438 patients treated within nine prospective randomized 
trials reported that, overall, of 49 (11%) patients achieving a CR, 
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Most first-line MBC patients in the historical studies had not 
received  any  previous  chemotherapy  (18–20).  Compared  with 
them, patients in modern series mostly relapse following adjuvant 
chemotherapy and unfortunately demonstrate lower response and 
survival rates (21).
The extensive literature available on first-line randomized clin-
ical  trials  with  modern  drugs  and/or  combinations  has  shown 
overall statistically significant improvements in response rates, but 
few studies have found clear survival benefits, and usually no data 
are provided on the proportion of long-term survivors. Any poten-
tial impact of first-line therapies on OS may also be confounded by 
the  effects  of  subsequent  effective  therapies;  when  testing  new 
drugs and/or treatment strategies, efforts to identify survival sur-
rogates have yielded discordant results and have not produced a 
validated tool to predict the long-term effects of chemotherapy in 
MBC (14,15,22–26).
Particularly interesting is the new scenario of potential long-
term disease control with targeted therapies. Because the duration 
of clinical experience with targeted agents is relatively short (tras-
tuzumab  received  Food  and  Drug  Administration  approval  in 
1998), few data exist on long-term outcomes of patients who are 
treated  with  these  compounds.  Published  case  reports  suggest, 
however, that at least in a small subpopulation of patients, long-
lasting remission can be achieved with these agents (27).
In  conclusion,  an  increasing  number  of  randomized  clinical 
trials  document  statistically  significant  improvements  in  disease 
control with modern chemotherapy in MBC. In addition, a small 
but recognizable subset of patients achieve long-term remission.
Is There a Role for High-Dose Chemotherapy?
Several trials have tested the hypothesis that high-dose chemo-
therapy (HDC) with autologous bone marrow or peripheral stem 
cell transplantation may improve survival in women with MBC. 
The  last  Cochrane  systematic  review  (28),  published  in  2005, 
examined six randomized controlled trials comparing the effec-
tiveness of HDC (438 patients overall) with conventional chemo-
therapy (412 patients). No statistically significant difference in 
OS was shown between the high-dose and the control groups at 
1, 3, or 5 years, despite a statistically significant difference in 
event-free survival favoring the high-dose group at 1 and 5 years 
of follow-up. In conclusion, due to the severe toxicity of HDC 
and the absence of a proven benefit, the final recommendation 
was to avoid the high-dose strategy outside of clinical trials (28). 
The  recent  randomized  trials  also  confirmed,  in  unselected 
patient populations, the lack of a benefit from HDC either up 
front  or  as  consolidation  after  response  to  standard  induction 
chemotherapy (29–35).
“Adjuvant” Systemic Therapy After Local 
Treatment
The  role  of  adjuvant  systemic  therapy  after  local  treatment  of 
solitary  metastases  (surgical  resection  or  radiation  therapy)  has 
been investigated in many nonrandomized trials. The addition of 
systemic therapy is based on the assumption that micrometastases 
exist in the majority of these patients and might be eradicated in at 
least some of them.
The  largest  experience  with  adjuvant  systemic  therapy  after 
local treatment of single distant metastases comes from a series of 
consecutive trials including 285 patients (the majority of whom 
had locoregional recurrence alone) conducted at the MD Anderson 
Cancer Center (36–39). In the three “anthracycline-based” trials, 
20-year disease-free survival (DFS) and OS reached 26%, confirming 
the possibility of achieving a long-term disease control. Among the 
53 patients with distant metastases, 12 (23%) achieved long-term 
disease control (6). In the newer “docetaxel-based” trial, among 26 
patients (12 of whom had only locoregional relapse), 5-year DFS 
and OS were 34% and 59%, respectively, with less favorable results 
in the subgroup with distant metastases (6). In these trials, a simul-
taneous control group with no chemotherapy was not considered 
appropriate,  and  the  results  were  compared  with  historical  data   
from the same institution, which showed a 15-year DFS rate of   
only 3%.
Limited data exist on the use of HDC as adjuvant treatment 
after radical local therapy of oligometastatic breast cancer. In a 
series  from  the  University  of  Colorado,  60  patients  (18  with 
locoregional recurrence only) underwent HDC with autologous 
stem cell transplantation after curative local treatment. Relapse-
free survival and OS at 5 years were achieved by 52% and 62% of 
patients, respectively (40). In a subgroup of patients with distant 
metastases  only  (without  concomitant  locoregional  recurrence), 
the 5-year relapse-free survival was 59%. Importantly, the trial 
excluded patients with brain or liver metastases, whereas patients 
with  limited  bone  marrow  involvement  were  included.  HER2 
overexpression, number of metastatic sites, and axillary nodal ratio 
(number of positive nodes divided by number of sampled nodes) 
were reported as independent outcome predictors, suggesting a 
possible prognostic model for relapse after HDC (41). Selection 
bias, limited number of patients, and lack of validation of the pro-
posed  model  in  a  different  larger  patient  population  prevent 
making any definite conclusions regarding the contribution of this 
treatment strategy to outcome.
In  conclusion,  available  data  suggest  that,  despite  important 
differences in patient characteristics and selection bias, at 5 years 
after local treatment for a locally recurrent or metastatic lesion 
followed by adjuvant systemic treatment, 36%–52% of patients 
remain alive and without evidence of relapse.
The utility of chemotherapy after locoregional treatment for iso-
lated locoregional recurrence (ie, not associated with distant metasta-
ses) is still an open question being currently investigated in a joint 
study by the International Breast Cancer Study Group (IBSCG) and 
the National Surgical Adjuvant Breast and Bowel Project (NSABP), 
under the umbrella of the Breast International Group (BIG).
Regional Chemotherapy
The ability to deliver higher concentrations of cytotoxic drugs to 
isolated tumor sites makes regional chemotherapy a possible alter-
native in patients with single metastatic foci, especially if not ame-
nable  to  other  local  treatments.  Small  case  series  of  regional 
hepatic intra-arterial therapy in patients with isolated liver metas-
tases  from  breast  cancer  have  been  reported  (42–45).  Tumor 
shrinkage  can  sometimes  be  dramatic  and  may  render  patients 
candidates  for  liver  resection  with  curative  intent,  potentially 
resulting in long-term DFS (46).jnci.oxfordjournals.org    JNCI | Commentary 459
The Role Of Local Treatment
Surgery for Primary Tumor in the Presence of Metastatic 
Disease
MBC at diagnosis constitutes 3.5%–7% of all new breast cancers 
(46); this apparently marginal problem involves about 7000 new 
patients every year in the United States alone, up to 50% of whom 
have locally operable (T1–T3) primary tumors (47). Traditionally, 
this group of patients was managed primarily with systemic modal-
ities, limiting local treatments to palliative management of uncon-
trolled local and/or regional disease (in form of so-called “toilette 
mastectomy” or low-dose radiotherapy).
The biological rationale for removing the primary tumor in 
case of proven disease dissemination is debatable. Several potential 
advantages have been proposed. By removing the primary tumor, 
one of the sources of further metastatic spread is eradicated (48–
52); this risk of reseeding is more relevant with the current im-
provements in systemic treatments (53). Data from animal studies 
suggest that removal of tumor bulk may restore immunocompe-
tence (54) because the primary tumor seems to modulate the im-
mune system through release of immunosuppressive factors (55). A 
reduction in the number of cancer cells may also lead to increased 
efficacy of systemic therapy by decreasing the risk of emergence of 
chemoresistant  cells  and  by  removal  of  necrotic  tumor  tissue 
poorly accessible to drugs (54). Debulking surgery has been proven 
clinically effective in other common solid tumors, such as ovarian, 
colorectal,  gastric,  renal  cancers,  and  malignant  melanoma 
(56–58).
However, some potential disadvantages of removing the pri-
mary tumor have also been proposed. Because the primary tumor 
is a source of antiangiogenic factors and growth factor inhibitors, 
there  may  be  an  accelerated  relapse  in  response  to  its  removal 
(49,59); however, the rush of angiogenesis in distant disease sites 
may  increase  the  chemosensitivity  of  malignant  cells  (60).  The 
possible release of growth factors related to surgical wounding (51) 
and the immunosuppression caused by surgery and anesthesia (61) 
are also potential disadvantages.
Several series evaluated the role of local treatment for the pri-
mary  tumor  in  patients  with  MBC  at  diagnosis  (Table  1) 
(50,55,62,63,64,66). Importantly, in patients with positive surgical 
margins, surgery did not add any substantial survival benefit as 
compared with patients who did not undergo surgery.
Interestingly, the percentage of MBC patients undergoing sur-
gery for the primary tumor in all these series is surprisingly high, 
ranging from 37% to 61.3% (49,50). These percentages reflect the 
ongoing change, despite the lack of randomized confirmatory data, 
in the perceived role of breast cancer surgery in the presence of 
metastatic  disease.  As  already  mentioned,  the  characteristics  of 
MBC have changed and hence the comparison with historical con-
trols  and  the  applicability  of  old  criteria  for  operability  clearly 
needs reevaluation. Overall, patients undergoing surgery are more 
likely to be younger, with smaller endocrine responsive tumors and 
more often have only a single metastatic site without visceral in-
volvement. Therefore, the benefit of surgery may, at least partially, 
be attributed to selection biases, such as surgical referral of patients 
with better general status, less advanced primary tumors, lower 
burden of metastatic disease, and better response to systemic treat-
ment (49,53). The question is whether these patients lived longer 
because of tumor removal or had their tumors removed because of 
a predicted longer survival (67). A publication bias of reporting 
preferably  the  positive  studies  also  cannot  be  excluded  (49). 
Nevertheless, results of multivariable analyses, which control for 
these confounding factors, consistently suggest a survival benefit 
for optimal local treatment of the primary tumor. Many questions 
still remain unsolved, including which patients could benefit most 
from surgery and what is its optimal timing and the best systemic 
treatment for these selected patients (51,53,68).
In conclusion, there is a bulk of retrospective data suggesting 
the importance of local treatment of primary tumor and strongly 
recommending  that  well-conducted  randomized  trials  are  per-
formed in this setting. One such trial is being developed under the 
joint effort of Breast International Group and the North American 
Intergroup. While waiting for data from these studies, surgery for 
breast primary tumor can be considered as a relatively inexpensive 
and low morbidity treatment, which can offer a rapid local control 
and has a potential for survival benefit, provided it is performed 
optimally.
Surgery for Lung and Liver Metastases
Several series have reported on lung and liver metastases resection 
in  MBC  (Tables  2  and  3):  most  data  are  from  small  series  of 
patients collected over many years. The largest dataset comes from 
the International Registry of Lung Metastases and presents results 
of lung metastasectomy in 467 breast cancer patients (70). Complete 
resection was possible in 84% of patients and led to a median sur-
vival of 37 months (5-year OS = 38%, 10-year OS = 22%).
Identified prognostic factors for lung resection include disease-
free interval and number of metastases (disease-free interval >36 
months  and  solitary  metastases  being  the  most  favorable),   
ER  status,  size  of  metastases,  completeness  of  resection,  and   
use  of  anatomical  resection  (as  opposite  to  wedge  resection)   
(69–71,72,74,76,77–79,81). Obviously, the reported data refer to a 
subset of patients who were selected for favorable prognostic fac-
tors,  and  any  comparison  with  surgically  untreated  patients  is 
threatened by serious biases.
Pulmonary resection in MBC patients, apart from its potential 
therapeutic value, is also an important diagnostic tool, especially in 
patients with a suspected first recurrence, allowing for differential 
diagnosis  with  second  primary  lung  cancers  and  benign  lesions 
(13,81). The proportion of lesions proved not to be breast cancer 
metastases  in  various  series  ranges  from  7%  to  66%  (70,73–
75,79,80,82,95,96). As the morbidity and mortality of pulmonary 
resection  has  decreased  substantially  over  the  last  decades,  this 
potentially  beneficial  procedure  can  be  discussed  in  a  selected 
group of patients (69–71,81).
Surgery  to  remove  liver  metastases  is  an  accepted  treatment 
modality in patients with colorectal cancer (97). Its role in breast 
cancer is, however, much less recognized. In various series of he-
patic resection for breast cancer metastases, the reported median 
survival ranged from 14.5 to 63 months and the 5-year survival 
from 14% to 61%, in general, comparing well with nonsurgically 
treated patients. Most of the reported series, however, describe ex-
tremely selected patients, constituting 1% or less of MBC patients 
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Table 1. Surgery for primary tumor in metastatic breast cancer patients*
First author 
(reference)
No. of patients:  
operated/all (%) Median OS (mo) 5-y OS (%)
HR for OS  
(surgery vs not)
Prognostic factors  
(multivariable analysis)
Khan,  
  2002 (50)
9162/16023 (57.2%) Total mastectomy: 31.9;  
  partial mastectomy: 26.9;  
  no surgery: 19.3
Margin (2): 35 (3y);  
  margin (+): 26 (3y);  
  no surgery: 17 (3y)
Margin (2): 0.61;  
  margin (+): 0.75
Surgical resection/margin  
  status, systemic treatment,  
  No. of metastatic sites, site  
  of metastases
Rapiti,  
  2006 (62)
127/300 (42%) Adjusted BCSS:  
  margin (2): 26†;  
  margin (+): 17*;  
  no surgery: 13†
BCSS:  
  margin (2): 27;  
  margin (+): 16;  
  no surgery: 12
BCSS:  
  margin (2): 0.6;  
  margin (+): NS
Surgery for primary, age,  
  method of diagnosis,  
  regional N involvement,  
  visceral or CNS metastases,   
  hormonal treatment
Gnerlich,  
  2007 (55)
4578/9734 (47%) Surgery: 27†;  
  no surgery: 12*
Surgery: 24†;  
  no surgery: 12†
0.63 Surgery, tumor size, tumor  
  grade, year of diagnosis,  
  use of RT
Blanchard,  
  2008 (63)
242/395 (61.3%) Surgery: 27.1;  
  no surgery: 16.8
Surgery: 22†;  
  no surgery: 7*
0.71 Definitive surgery, ER status,  
  PgR status, No. of  
  metastases
Babiera, 2006 (51);  
  Rao, 2008 (64)
82/224 (37%) Not reached;  
  predicted: 54
ND (median fu  
  32.1 mo)
0.5 Definitive surgery (trend), No.   
  of metastatic sites, HER2  
  status
Fields, 2007 (52) 187/409 (45.7%) Surgery: 26.8;  
  no surgery: 12.6
Surgery: 28†;  
  no surgery: 12*
0.53 Definitive surgery, site of  
  metastases
Khan, 2003 (65) 5179/9197 (56.3%) ND Margin (2): 34.2 (3y);  
  margin (+): 26.8 (3y);  
  no surgery: 17.5 (3y)
0.67 Surgery with (2) margins
Carmichael,  
  2003 (66)
20/? 23 ND N/A ND
*  BCSS = breast cancer–specific survival; CNS = central nervous system; ER = estrogen receptor; HR = hazard ratio; N = nodal; N/A = not applicable; ND = no data; 
NS = non-statistically significant; OS = overall survival; PgR = progesterone receptor; RT = radiotherapy.
†  Data from survival curves.
Table 2. Resection of pulmonary metastases from breast cancer*
First author  
(reference)
No. of  
patients
Median  
OS (mo) 5-y OS (%)
Friedel, 2002 (70) 467 35 35
Planchard, 2004 (69) 125 50 45
Friedel, 1994 (71) 91 ND 27
Murabito, 2000 (72) 62 (28  
  complete  
  resection)
Complete  
  resection: 79;  
  incomplete  
  resection: 15.5
Complete  
  resection: 80
McDonald, 1994 (73) 60 42 37.8
Livartowski, 1998 (74) 40 70 54
Tanaka, 2005 (75) 39 32 30.8
Lanza, 1992 (76) 37 47 49.5
Staren, 1992 (77) 33 58  
  (single  
  metastasis)
36
Girard, 1994 (78) 32 ND ND
McCormack,  
  1978 (79)
28 20 15
Rena, 2007 (80) 27 ND 38
Ludwig, 2003 (81) 21 96.9 53
Mountain, 1978 (82) 21 27 14
*  ND = no data; OS = overall survival.
Table 3. Resection of liver metastases from breast cancer*
First author (reference)
No. of  
patients
Median  
OS (mo) 5-y OS (%)
Adam, 2006 (83) 85 46† 41†
Pocard, 2001 (84) 65 ND 46 (4-y)
Elias, 2003 (85) 54 34 34
Pocard, 2000 (86) 52 42 65 (3-y)
Raab, 1998 (87) 34 27 18.4
Sakamoto, 2005 (88) 34 36 21
Vlastos, 2004 (89) 31 63 61
Yoshimoto, 2000 (90) 25 42† 33†
Elias, 1995 (91) 21 38.2† 24†
Ercolani, 2005 (92) 21 40.3 25
Singletary, 2003 (13) 21 40 (DFS) 55 (3-y DFS)
Pocard, 1997 (93) 21 ND 60
*  DFS = disease-free survival; ND = no data; OS = overall survival.
†  Since diagnosis of liver metastases.
example, in the series of Pocard et al. (86), all patients were asymp-
tomatic and identified through intensive surveillance programs.
Interestingly,  in  contrast  to  lung  metastases,  where  most  of 
resected patients develop recurrence outside the lung or with dis-
seminated disease, in case of hepatic resections, most recurrences 
occur in the liver (96). Repeated resection gives favorable results in 
some of these patients (83). Importantly, the selection criteria for 
surgery constitute favorable prognostic factors per se: consequently, 
the reported results need to be viewed with caution even though 
the safety of hepatic resection has improved during the last decades 
(89,96).
Radiofrequency ablation is a relatively new treatment mo-
dality that uses thermal energy to induce coagulation necrosis 
in tumor cells. Effective local control can be achieved in solitary 
lesions less than 3 cm in diameter; thus, this therapy provides jnci.oxfordjournals.org    JNCI | Commentary 461
promising survival rates in patients with no visceral extrahepatic 
disease or with single bone metastases (99,100,101). Local man-
agement of brain and bone metastases will be the subject of a 
separate manuscript.
In summary, available data demonstrate favorable results in a 
subset of patients undergoing “radical” local therapy for metastatic 
disease.  Selection  bias  and  the  retrospective  nature  of  available 
data do not allow for generalization of the results, and the use of 
such approaches must be individualized.
Conclusions
The presented data, overall, seem to suggest the possibility of a 
curative, multidisciplinary therapeutic approach for at least a frac-
tion of patients with limited MBC. Definitive evidence from con-
trolled prospective randomized trials is missing; available data are 
coming essentially from retrospective series, most with relatively 
few patients enrolled.
Because  patients  who  are  potentially  eligible  for  this  thera-
peutic strategy represent only 1%–3% of the total MBC popula-
tion, a large global collaboration is needed to confirm its impact on 
long-term survival or cure and to ensure adequate statistical power 
and strength of the results. Enrolled patients must have compa-
rable clinical and biological characteristics, extent of staging, and 
frequency of monitoring to avoid selection biases and stage migra-
tion, which can substantially affect the outcome.
The clinical consequences of confirming this hypothesis would 
be considerable. First, it would suggest that a selected subset of 
MBC patients should be approached with curative, not palliative, 
intent. Second, the current minimalistic postoperative monitoring 
should be revised to allow early diagnosis of low-burden disease 
relapse. The crucial issue of follow-up and its consequences will be 
addressed in detail by the Task Force in a separate manuscript. As 
a  consequence,  a  rigorous  economic  evaluation  would  also  be 
required to calculate the cost to benefit ratio and the assessment of 
personal and social impact of this shift in the management of MBC 
patients.
New predictive markers of sensitivity to selected therapies and 
innovative evaluation criteria to assess long-term treatment effi-
cacy will be the essential prerequisites to address the biological 
complexity and heterogeneity of MBC. The ultimate goal is to 
optimize the efficacy of individualized therapeutic strategies.
Very importantly, all available treatment options should be dis-
cussed with the individual patient with a clear explanation of the 
risk to benefit ratio. It is also important to recognize that the defi-
nition of “breast cancer survivor” has evolved and is subject to dif-
ferent interpretations. In the past, survivor was almost exclusively 
used to describe someone who was free of disease 5–10 years after 
diagnosis. More recently, it has become a dynamic concept that 
affirms the potential for quality living after a breast cancer diagno-
sis, therefore also including maximizing health and well-being if 
recurrence occurs and while living with metastatic disease.
Based on the available data, the ESO–MBC Task Force retains 
its original recommendation statement: “A small but very important 
subset of MBC patients, for example, those with a solitary meta-
static lesion, can achieve complete remission and a long survival.   
A more aggressive and multidisciplinary approach should be con-
sidered for these selected patients. A clinical trial addressing this 
specific situation is needed.”
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